Abivax’s lead asset is obefazimod, an anti-inflammatory drug that has produced positive Phase III results.
JPM26: Eli Lilly reportedly eyes €15bn takeover of Abivax
January 12, 2026
You may also like
Indices by TradingView
Missed Your RMD? You May Still Be Able to Avoid a Penalty.
February 8, 2026
Corning Rallies As Meta Deal And Project Vault Shape Growth Story
February 7, 2026
Categories
Indices by TradingView



